While molecularly targeting oncogenic KRAS-driven malignancies has long been deemed impossible, the introduction of Sotorasib (AMG-510) as first-in-class small molecule KRAS G12C inhibitor has dramatically changed this paradigm and in fact now represents a standard therapeutic option for KRAS G12C mutant NSCLC patients [52]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.